Pulmonx
LUNG on Nasdaq. Market value $81m.
Should I look at this?
We have not checked this company yet
This is not advice.
Who owns it
None of the long-term investors we follow own it. 108 funds in all.
Largest holders overall
- Primecap Management$6mCut
- Morgan Stanley$4mCut
- Soleus Capital Management, L.P.$4m
- Vanguard Capital Management$2m
- ExodusPoint Capital Management, LP$2mCut
- Almitas Capital$1mNew
- BlackRock$1mCut
- Stonepine Capital Management$1mAdded
- Jane Street Group$985,700Added
- Braidwell LP$978,303
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
3 investors own more than 5%.
- PRIMECAP MANAGEMENT CO/CA/Passive investor12.2%−1.4 ptsSince 30 September 2025
- Morgan StanleyPassive investorat least 6.9%−1.6 pts(filed with 1 related holder)Since 30 June 2026
- Soleus Capital Master Fund, L.P.Passive investorat least 6.5%(filed with 5 related holders)Since 6 March 2026
- BlackRock, Inc.Passive investorSold down below 5%Since 30 June 2026
- FMR LLCPassive investorSold down below 5%Since 31 October 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
| Holder | Stake | Since | |
|---|---|---|---|
PRIMECAP MANAGEMENT CO/CA/ Passive investor | 12.2%−1.4 pts | 30 September 2025 | |
Morgan Stanley Passive investor | at least 6.9%−1.6 pts (filed with 1 related holder) | 30 June 2026 | |
Soleus Capital Master Fund, L.P. Passive investor | at least 6.5% (filed with 5 related holders) | 6 March 2026 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 June 2026 | |
FMR LLC Passive investor | Sold down below 5% | 31 October 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 5 sold $547,892, $46,409 of it under preset trading plans.
- Radhakrishnan SrikanthChief Science & Techn. OfficerSold
- Date
- 1 September 2026
- Shares
- 14,245
- Price
- $2.26
- Value
- $32,194
- French Glendon E. IIIPresident and CEO, DirectorSold
- Date
- 1 September 2026
- Shares
- 41,882
- Price
- $2.26
- Value
- $94,653
- Rose Geoffrey BeranChief Commercial OfficerSold
- Date
- 1 September 2026
- Shares
- 7,879
- Price
- $2.26
- Value
- $17,807
- Lehman David AaronGeneral CounselSold
- Date
- 1 September 2026
- Shares
- 14,334
- Price
- $2.26
- Value
- $32,395
- French Glendon E. IIIPresident and CEO, DirectorSold
- Date
- 2 June 2026
- Shares
- 13,511
- Price
- $1.57
- Value
- $21,212
- Radhakrishnan SrikanthChief Science &Techn. OfficerSold
- Date
- 1 June 2026
- Shares
- 14,497
- Price
- $1.54
- Value
- $22,325
- French Glendon E. IIIPresident and CEO, DirectorSold
- Date
- 1 June 2026
- Shares
- 42,638
- Price
- $1.54
- Value
- $65,663
- Rose Geoffrey BeranCHIEF COMMERCIAL OFFICERSold
- Date
- 1 June 2026
- Shares
- 8,023
- Price
- $1.54
- Value
- $12,355
- Lehman David AaronGENERAL COUNSELSold
- Date
- 1 June 2026
- Shares
- 14,594
- Price
- $1.54
- Value
- $22,475
- Radhakrishnan SrikanthChief Science &Techn. OfficerSold
- Date
- 2 March 2026
- Shares
- 10,483
- Price
- $1.43
- Value
- $14,991
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 1 September 2026 | Radhakrishnan Srikanth Chief Science & Techn. Officer | Sold | 14,245 | $2.26 | $32,194 |
| 1 September 2026 | French Glendon E. III President and CEO, Director | Sold | 41,882 | $2.26 | $94,653 |
| 1 September 2026 | Rose Geoffrey Beran Chief Commercial Officer | Sold | 7,879 | $2.26 | $17,807 |
| 1 September 2026 | Lehman David Aaron General Counsel | Sold | 14,334 | $2.26 | $32,395 |
| 2 June 2026 | French Glendon E. III President and CEO, Director | Sold | 13,511 | $1.57 | $21,212 |
| 1 June 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sold | 14,497 | $1.54 | $22,325 |
| 1 June 2026 | French Glendon E. III President and CEO, Director | Sold | 42,638 | $1.54 | $65,663 |
| 1 June 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Sold | 8,023 | $1.54 | $12,355 |
| 1 June 2026 | Lehman David Aaron GENERAL COUNSEL | Sold | 14,594 | $1.54 | $22,475 |
| 2 March 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sold | 10,483 | $1.43 | $14,991 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 10 Mar 2026, plus the 10-Q filed 4 Aug 2026 and 3 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.